Printer Friendly

Evotec and UCB enter into sign multi-year CNS pharmacology agreement.

M2 EQUITYBITES-October 21, 2016-Evotec and UCB enter into sign multi-year CNS pharmacology agreement

(C)2016 M2 COMMUNICATIONS http://www.m2.com

Evotec AG (FRA:EVT), a drug discovery alliance and development partnership company, announced on Thursday a collaboration with UCB to provide a broad range of in vitro pharmacology services.

Under the terms of the three-year agreement, financial details of which were not disclosed, Evotec will support UCB's in vitro pharmacology team in drug discovery projects across multiple target classes, particularly in the CNS space.

Reportedly, key activities of this collaboration will include assay development, compound profiling and mechanistic studies and will provide UCB with access to key Evotec expertise in the field of in vitro pharmacology and electrophysiology.

UCB is a global biopharmaceutical company with a portfolio of small molecules and antibody based therapies for the treatment of severe immune-mediated diseases and central nervous system disorders.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Oct 21, 2016
Words:158
Previous Article:Blueknight's board to pay quarterly distributions on common & preferred units.
Next Article:Eiger BioPharmaceuticals doses first Phase 2 LIMT HDV study patient.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters